SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus as massive trading volume coincides with speculative interest in its recent $6.9 million counter-drone contract and a potential squeeze setup. Community members are divided, with many debating the stock's long-term defense sector fundamentals against intense short-selling pressure and concerns over share dilution.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as investors actively track its move above the 200-day moving average and speculate on a potential short squeeze amid rising volume and analyst price target upgrades. The community remains deeply divided, with bulls pointing to strong operational growth and potential buybacks while bears warn of technical resistance, recurring sell-offs, and historical volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as positive regulatory developments, including the potential passage of the CLARITY Act and institutional adoption, fuel strong buyer momentum. Investors are actively discussing the stock's consolidation patterns and its role as a key proxy for broader crypto-market recovery.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors debate whether the current price represents a strategic buying opportunity near long-term support or a continued decline fueled by competitive pressure and retail sentiment. Community discussion is sharply divided between bulls citing the long-term potential of the Pepsi distribution deal and international expansion, and bears emphasizing ongoing short interest and worries over slowing growth.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is at the center of heated community debate as traders monitor developments regarding the potential passage of the Clarity Act and its expected impact on institutional adoption. Investors are divided between optimism over regulatory progress and skepticism fueled by ongoing price stagnation, with many actively debating whether the current market environment signals a bottom or further downside.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending following a significant surge in trading volume and share price movement, largely driven by institutional accumulation and investors positioning ahead of upcoming quarterly earnings. The community is actively discussing the potential for a short squeeze, the company's expanding treatment center network, and the anticipation of pivotal clinical data readouts for non-small cell lung cancer (NSCLC) later this year.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp. is experiencing intense volatility as the market digests its recent quarterly earnings, with the community actively debating whether the current price represents a bargain or a warning sign after a steep post-earnings decline. Investors are fixated on guidance for product revenue growth, the status of its high-performance power modules in AI data centers, and legal developments concerning patent litigation that could impact future licensing revenue.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant investor attention following a federal executive order aimed at accelerating psychedelic research, combined with strategic leadership updates including the appointment of a new SVP of Medical Affairs. The community is actively debating the company's long-term outlook, weighing its Breakthrough Therapy status against concerns over recent leadership turnover, cash burn, and the potential for equity dilution.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently trending as investors weigh the potential of the commercial rollout of ZEVASKYN against recent price volatility and concerns regarding the pace of patient treatment scaling. Community members are actively debating the company's long-term commercial execution and the impact of the Qualified Treatment Center network expansion, with many viewing current price levels as a favorable entry point for a long-term position.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors digest a recent beat-and-raise quarterly report, which has sparked intense debate over the disconnect between strong fundamental guidance and the stock's recent price volatility. While community sentiment remains split between bullish value-seekers highlighting a solid backlog and bearish traders expressing frustration over institutional shorting pressure and management performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Nymox Pharmaceutical Corp

Neutral Sentiment

Too early to tell

Memory stocks have been under significant selling pressure in recent weeks. Is the selloff done? Cast your vote and drop your reasoning in the comments.

Is the pullback in memory stocks over? 
 
Explain your reasoning in the comments.

Current Price	$0.095
Prev Close	$0.095
Open	$0.095
Dividend Yield	N/A
50-Day Moving Average	$0.101
Beta	-7.74
Avg. Volume	68,152.67
PE Ratio	N/A

52-Week High	$0.1999
52-Week Low	$0.03
Market Capitalization	$8.98M
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

NYMXFNymox Pharmaceutical Corp

Latest NYMXF News